Strong Buy
Average AnalystStrong Buy
Top AnalystSlightly Bearish
Stock Target AdvisorStrong Buy
Average UserUSD 0.90
+0.00 (+0.11%)
USD 0.08B
0.63M
USD 5.80(+543.73%)
Based on the Adicet Bio Inc stock forecast from 4 analysts, the average analyst target price for Adicet Bio Inc is USD 5.80 over the next 12 months. Adicet Bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Adicet Bio Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Adicet Bio Inc’s stock price was USD 0.90. Adicet Bio Inc’s stock price has changed by -2.05% over the past week, -1.76% over the past month and -72.45% over the last year.
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector